Importantly, the strength of this association appears highly context-dependent: enhanced NK-cell activity correlates more consistently with clinical benefit in tumors exhibiting immunogenic characteristics, such as elevated PD-L1 expression or high tumor mutational burden, and in histological subtypes characterized by greater NK infiltration, which is more frequently observed in squamous carcinoma than in adenocarcinoma (107, 108). The gene discussed is CD274; the disease is neoplasm.